Author: Teoh, Kim-Tat; Siu, Yu-Lam; Chan, Wing-Lim; Schlüter, Marc A.; Liu, Chia-Jen; Peiris, J. S. Malik; Bruzzone, Roberto; Margolis, Benjamin; Nal, Béatrice
Title: The SARS Coronavirus E Protein Interacts with PALS1 and Alters Tight Junction Formation and Epithelial Morphogenesis Document date: 2010_11_15
ID: ufw13pjx_56
Snippet: We then hypothesized that E CT could compete with CRB3 CT, a natural ligand of PALS1 PDZ domain, and affect CRB3-PALS1 interaction. To verify this hypothesis, we designed two peptides corresponding to the CT tails of E (amino acids 34-76) and CRB3 (amino acids 80-120) and tested their capacity to interfere with the interaction between CRB3 and PALS1 PDZ domain in a GST-pull down assay (Figure 4C). Briefly, the peptides (0.2–1 mM in DMSO) were i.....
Document: We then hypothesized that E CT could compete with CRB3 CT, a natural ligand of PALS1 PDZ domain, and affect CRB3-PALS1 interaction. To verify this hypothesis, we designed two peptides corresponding to the CT tails of E (amino acids 34-76) and CRB3 (amino acids 80-120) and tested their capacity to interfere with the interaction between CRB3 and PALS1 PDZ domain in a GST-pull down assay (Figure 4C). Briefly, the peptides (0.2–1 mM in DMSO) were incubated with 1 μg of GST-PDZ fusion protein for six hours at 4°C. As control, GST-PDZ fusion proteins were incubated with DMSO in absence of peptide. The inhibitory complexes (GST-PDZ fusion proteins bound with E or CRB3 peptides) formed were not washed and cell lysate containing either myc-CRB3 or HA-E (wt) proteins were added immediately, followed by overnight incubation at 4°C. The precipitated interacting proteins were determined by immunoblotting using a rabbit anti-CRB3 serum (Figure 4C, panel a) and a mouse IgG1 monoclonal anti-HA antibody (Figure 4C, panel b), respectively.
Search related documents:
Co phrase search for related documents- amino acid and capacity test: 1
- amino acid and cell lysate: 1, 2, 3, 4, 5, 6
- amino acid and CT tail: 1, 2, 3
- amino acid and DMSO mM peptide: 1
- amino acid and fusion protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75
- amino acid and gst pull: 1, 2, 3
- amino acid and gst pull assay: 1, 2
- amino acid and hypothesis verify: 1
- amino acid and interact protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
- amino acid and interaction affect: 1, 2, 3, 4, 5
- amino acid and pals1 pdz domain: 1
- amino acid and pdz domain: 1, 2, 3, 4
- amino acid and peptide absence: 1
- amino acid and wt protein: 1, 2, 3, 4, 5, 6
- anti ha antibody and CT tail: 1
- anti ha antibody and fusion protein: 1
- anti ha antibody and overnight incubation: 1
- anti ha antibody and pals1 pdz domain: 1
- anti ha antibody and pdz domain: 1
Co phrase search for related documents, hyperlinks ordered by date